Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
allogeneic Vγ9Vδ2 T cells (Beijing Tiantan Hospital)
- Development stage
- Unknown
- Lead developer
- Beijing Tiantan Hospital
- Modality
- Cell Therapies
- Administration
- Intracerebroventricular
01
Overview
An allogeneic Vγ9Vδ2 T cell immunotherapy being developed by Beijing Tiantan Hospital for the treatment of malignant gliomas, including glioblastoma multiforme (GBM) and diffuse intrinsic pontine glioma (DIPG). These cells are a subset of gamma-delta T cells that recognize phosphoantigens, such as isopentenyl pyrophosphate (IPP), which accumulate in glioma cells due to dysregulated cholesterol metabolism. This recognition is mediated by the butyrophilin molecules BTN3A1 and BTN2A1 and occurs independently of the major histocompatibility complex (MHC), facilitating allogeneic transplantation without the need for HLA matching. The therapy is administered locally into the cerebral ventricles via an Ommaya capsule to bypass the blood-brain barrier and directly target the tumor site.
- Other names
- Vγ9Vδ2 T cellsallogeneic gamma-delta T cells
02
Targets
BTN2A1 (Butyrophilin subfamily 2 member A1)BTN3A1 (Butyrophilin subfamily 3 member A1)
Beyond the preview
Go deeper on allogeneic Vγ9Vδ2 T cells (Beijing Tiantan Hospital).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on allogeneic Vγ9Vδ2 T cells (Beijing Tiantan Hospital).